Regeneron Pharmaceuticals, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Regeneron Pharmaceuticals has scheduled its 2025 Annual Meeting for June 13, 2025, and is soliciting shareholder votes on key proposals, including the election of directors, ratification of the company's independent auditor, executive compensation, and amendments to the company's Certificate of Incorporation.
NASDAQ
Regeneron Pharmaceuticals aims to enhance shareholder value through proposed governance changes, including board declassification and elimination of supermajority voting requirements.
NASDAQ
DEFA14A: Regeneron Pharmaceuticals Sets Date for 2024 Annual Meeting, Outlines Proposals for Shareholder Vote
Regeneron Pharmaceuticals has scheduled its annual shareholder meeting for June 14, 2024, and is soliciting votes on key proposals including the election of directors, ratification of auditors, and executive compensation.
NASDAQ
Regeneron's 2024 proxy statement outlines the company's dedication to innovation, pipeline advancement, and corporate responsibility, reflecting a strong financial position and a commitment to shareholder value.